Chloroform Extract of Solanum trilobatum Inhibits the Progress of Ehrlich Ascites Carcinoma in Mice

This study was initiated to evaluate the modulating effect of chloroform extract of Solanum trilobatum (CST) on Ehrlich Ascites Carcinoma (EAC) in mice. In vitro cytotoxicity of CST on Ehrlich Ascites Cells (EAC) and Human Leukemic cells (HL-60 cells) were evaluated using trypan blue staining. To study the in vivo effect of CST, tumors were introduced into experimental animals by intraperitoneal injection. Animals were treated with CST (400 mg kgG b.wt., after 24 h and 7 days of tumor inoculation for five alternate days. Cisplatin, an antitumor drug (2 mg kgG b.wt.,) was used as a positive control starting from first and the seventh day of tumor inoculation, respectively. After the experimental period, antitumor parameters (ascitic tumor volume, mean survival time and viability of tumor cells), hematological studies and biochemical parameters (activities of SGOT, SGPT, ALP and LDH) were measured. Results showed that CST strongly inhibited the growth of HL-60 and EAC cell line in in vitro condition. In in vivo conditions, administration of CST reduced the tumor volume and the viability of tumor cells as well as increased the mean survival time of EAC inoculated mice. Activities of liver enzymes were found to be restored by the administration of CST. Histopathological examination showed that CST was capable of reducing the damage caused to the liver by the excessive tumor growth. The cytotoxic and antitumor effect demonstrated by this study supported the fact that the antioxidant components present in CST may be a promising source of antitumor compounds for managing different types of cancer.